Walleye Capital
SPRY icon

Walleye Capital’s ARS Pharmaceuticals SPRY Stock Holding History

Walleye Capital’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-36,862
Closed -$370K – 5101
2025
Q3 		$370K Buy
+36,862
New +$529K ﹤0.01% 2838
2024
Q3 		– Sell
-71,499
Closed -$608K – 5831
2024
Q2 		$608K Buy
+71,499
New +$635K ﹤0.01% 3336
2021
Q4 		– Sell
-92,654
Closed -$925 – 2300
2021
Q3 		$925 Buy
+92,654
New +$2.28M 0.03% 481

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Walleye Capital's SPRY Position: Q4 2025 in Review

Walleye Capital sold out of ARS Pharmaceuticals (SPRY) in Q4 2025, closing a stake of 36,862 shares — an estimated $370K sold.

Walleye Capital first reported a position in SPRY in Q3 2021 and held it in 3 quarters. The position peaked at $608K in Q2 2024. 189 funds tracked by Wall St. Rank hold SPRY as of Q4 2025.

  • Walleye Capital reported no remaining ARS Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Walleye Capital sold 36,862 ARS Pharmaceuticals shares in Q4 2025, an estimated $370K.
  • Walleye Capital first reported a position in ARS Pharmaceuticals in Q3 2021 and held it in 3 quarters.
  • Walleye Capital's ARS Pharmaceuticals position peaked at $608K in Q2 2024.
  • 189 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q4 2025.

Based on Walleye Capital's 13F filing for Q4 2025, filed 13 Feb 2026.